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• This is the ﬁrst study on the effect of Cognitive Remediation (CR) on negative symptoms in people with schizophrenia.
• The results demonstrate a small to moderate effect of CR on negative symptoms (effect size g =−0.30).
• Negative symptom reduction is maintained at follow-up (effect size 95% g =−0.36).
• Studies with more robust methodology show a larger negative symptom reduction (effect size g =−0.40).
• There were no differences in drop-out rates between individuals randomized to CR and the control conditions suggesting that this intervention is acceptable.
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Cognitive remediation (CR) is a treatment targeting cognitive difﬁculties in peoplewith schizophrenia. Recent re-
search suggested that CR may also have a positive effect on negative symptoms. This meta-analysis investigates
the effect of CR on negative symptoms.
A systematic search was used to identify all randomized-controlled trials of CR in people with schizophrenia
reporting negative symptoms outcomes. Levels of negative symptoms at baseline, post-therapy and follow-up,
sample demographics and treatment length were extracted. Study methodological quality and heterogeneity
were addressed. Negative symptoms standardized mean change was calculated using Hedges's g and used as
the main outcome.
The search identiﬁed 45 studies reporting results for 2511 participants; 15 studies reported follow-up outcomes.
CRwas associatedwith a reduction of negative symptoms (most conservativemodel g=−0.30; 95% CI:−0.36,
−0.22) at post-therapy compared with treatment as usual and this effect was larger at follow-up (g=−0.36;
95% CI:−0.51,−0.21). Drop-out rate was comparable between conditions. Network meta-analysis conﬁrmed
CR was superior to TAU and TAU plus active control or adjunctive treatment. No evidence of publication bias
was found. Studies with more rigorous methodology were associated with larger negative symptom reduction
(g=−0.40; 95% CI:−0.51 to−0.30).
Although negative symptoms have not been considered a primary target for CR, this intervention can have small
tomoderate beneﬁcial effects on this symptom cluster. Future research should explore in detail the active mech-
anisms responsible for negative symptom reduction and the relationship between cognitive and negative symp-
toms in schizophrenia.
© 2016 Published by Elsevier Ltd.
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1. Introduction
Cognitive remediation (CR) is a behavioural intervention aiming to
improve cognitive processes in neuropsychiatric disorders. CR relies
largely on learning principles such as repeated and personalised task
practice, tailored feedback and the teaching of compensatory methods
to overcome cognitive related problems. The consolidated notion of
widespread cognitive difﬁculties in people with schizophrenia
prompted the application of this intervention in this illness domain
(Keshavan, Vinogradov, Rumsey, Sherrill, & Wagner, 2014;
Vinogradov, Fisher, & de Villers-Sidani, 2012). To date a relatively
large number of studies that appear in the literature, systematic reviews
and meta-analyses suggest that CR has beneﬁcial effects on both cogni-
tion and functioningwith small tomoderate effect sizes (Wykes, Huddy,
Cellard, McGurk, & Czobor, 2011). The most recent meta-analysis also
suggests that CR has a small effect on symptoms; however, this study
considered only global symptoms and did not distinguish between dif-
ferent dimensions (Wykes et al., 2011).
Schizophrenia is a heterogeneous condition comprising different
symptom clusters. Themost reported symptom dimensions in the liter-
ature are positive and negative symptoms.While antipsychotic medica-
tions have proven beneﬁcial for themanagement of positive symptoms,
pharmacological treatments have still not provided convincing beneﬁts
for negative symptoms (Fusar-Poli et al., 2014). Negative symptoms
have often been found to contribute to long term illness features includ-
ing poor community and social functioning and to negatively inﬂuence
recovery and general health outcomes (Ventura et al., 2015).
Research has suggested that negative symptomsmay partially over-
lap with cognitive difﬁculties. Negative symptoms have been shown to
correlate with poor cognitive resources, difﬁculties in the generation
and execution of cognitive strategies, slow responses on simple atten-
tion tasks, poor abstract reasoning and impaired set shifting
(Heydebrand et al., 2004), while positive symptoms appear to correlate
only with inhibition difﬁculties (Waters, Badcock, Maybery, & Michie,
2003). Reviews and longitudinal studies have further conﬁrmed the as-
sociation between negative symptoms and cognitive impairment in
people with schizophrenia (Rund, 1998). Evidence from animal models
also suggests that similar neural pathways may underlie the processes
involved in components of both negative symptoms and cognitive im-
pairments (Karlsson et al., 2009; Labrie, Lipina, & Roder, 2008).
The primary target of CR is cognition but most interventions consid-
er cognitive improvement as a means to achieve higher functioning
levels (Wykes, Reeder, et al., 2007; Wykes, Newton, et al., 2007).
There are also reports that CR has a small effect on the symptoms of
schizophrenia (Wykes et al., 2011). The majority of these studies con-
verge in suggesting that this effect is more evident for negative com-
pared to positive symptoms (Cella, Reeder, & Wykes, 2014; Farreny,
Aguado, Ochoa, Haro, & Usall, 2013; Sanchez et al., 2014).
1.1. How CR may impact on negative symptoms of schizophrenia
Strauss and Gold (2012) suggested that problems in the domain of
working memory may negatively inﬂuence motivation and the experi-
ence of pleasure. These authors hypothesised that working memory
problems may have a negative impact on representing and accessing
past experiences with a subsequent negative effect on estimates of fu-
ture enjoyment and motivation.
A similar mechanism of action is through improving reward sensi-
tivity. People with schizophrenia have difﬁculties in using feedback,
particularly positive feedback, to modify their behaviour (Strauss,
Waltz, & Gold, 2014). Lack of response to positive feedback can be asso-
ciated with a number of negative symptoms such as apathy, anhedonia,
amotivation and social withdrawal (Gold, Waltz, Prentice, Morris, &
Heerey, 2008). Recent research showed that CR can improve reward
sensitivity in people with schizophrenia and indicated that sensitivity
to feedback is inversely associated with negative symptoms severity
(Cella, Bishara, et al., 2014).
CR may also affect negative symptoms by inﬂuencing executive
functions. The behavioural components of negative symptoms, linked
to withdrawal and poor motivation, may depend on poor planning
and difﬁculties in sequencing actions to complete a complex task. The
association between improvement in executive function and reduction
in negative symptomshas been highlighted in a recent study suggesting
that CR may exert an indirect effect on negative symptom via executive
function (Farreny et al., 2013).
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It is possible that CR may exert an effect on negative symptoms by
improving self-esteem and conﬁdence. Studies showed that cognitive
problems in people with schizophrenia are associated with reduced
self-esteem (Cella, Swan, Medin, Reeder, & Wykes, 2014) and that CR
beneﬁts on cognition are often associated with a self-esteem boost
(Kidd et al., 2014; Ostergaard Christensen et al., 2014). Increased self-
esteem after CRmay counter negative symptoms by challenging defeat-
ist beliefs, avoidant behaviour and poor motivation.
Despite a number of positive reports of potential mechanisms of ac-
tion there is still no systematic evidence showing that CR can be beneﬁ-
cial for negative symptoms and there is no indication of its effect size.
With a restricted number of interventions available that beneﬁt nega-
tive symptoms it is important to investigate the putative advantage
that awell-established intervention, such as CR,mayhave on this symp-
tom cluster. For this reason the current study sets out to assess the po-
tential usefulness of CR for negative symptoms.
In this study we ﬁrst determine the clinical effectiveness (i.e. effect
sizes) of CR compared to treatment as usual and active control using a
pairwise and network-meta analysis approach at end of therapy and
at follow-up. Secondly, we evaluate the role of moderating factors in-
cluding age, gender, studymethodological quality and therapy duration.
Lastly, we will determine the acceptability of this treatment option and
evaluate treatment retention rates.
2. Methods
This review was conducted according to the Preferred Reporting
Items for Systematic Reviews andMeta-Analyses (PRISMA)methodolo-
gy. The study protocol was published online on the PROSPERO database
on November 12th 2014 (http://www.crd.york.ac.uk/PROSPERO/
display_record.asp?ID=CRD42014014529).
2.1. Literature search
2.1.1. Electronic searches
Multiple systematic searches were conducted using the following
databases: MEDLINE, Embase, Web of Science, PsycInfo and Cochrane
Collaboration Controlled Trials Register. The following search terms
were used as either key terms or keywords: (“cognitive” or “cognit*”)
AND (“training” or “remediation” or “rehabilitation” or “enhancement”)
AND “schizophrenia” AND (“random” or “randomized control trial” or
“clinical trial”).
2.1.2. Other resources
References of recent meta-analyses were inspected to identify pa-
pers potentially missed by the electronic search. Members of the Cogni-
tive Remediation Experts Workshop group were contacted regarding
outstanding CR trials.
2.2. Studies included
All relevant studies were considered eligible if they included:
randomisation; an appropriate comparison group (i.e. treatment as
usual or another active treatment); N75% of participants had a diagnosis
of schizophrenia or schizoaffective disorder (see participants section for
details); received a form of CR (see intervention section for deﬁnition)
appropriate intervention; assessed negative symptoms using a validat-
ed measure.
2.3. Participants
Adults (aged 18+) with a diagnosis of schizophrenia or
schizoaffective disorder according to theDiagnostic and StatisticalMan-
ual of Mental Disorder (American Psychiatric Association, 2013), Re-
search Diagnostic Criteria (Spitzer, Endicott, & Robins, 1978) or
International Classiﬁcation of Diseases (World Health Organisation,
1992). Studies including participants with other diagnosis in the psy-
chosis spectrum were included only if participants with a diagnosis of
schizophrenia or schizoaffective disorders were N75% of the partici-
pants considered.
2.4. Intervention
The intervention is a course of CR conducted according to principles
includingmassed practice, errorless learning and scaffolding and had to
target one or more cognitive domains as primary targets. Both
computerised and pencil and paper CR were considered. We did not
consider CR interventions primarily focussed on psychoeducation relat-
ed to cognitive problems.
2.5. Negative symptom assessment
Only studies using a validated symptom assessment measures pro-
viding an assessment of negative symptoms were used. These include
the Positive and Negative Symptom Scale (PANSS) (Kay, Fiszbein, &
Opler, 1987), Brief Psychiatric Rating Scale (BPRS) (Overall & Gorham,
1962) and the Symptom Assessment for Negative Symptoms (SANS)
(Andreasen, 1982).
2.6. Data collection
Two authors (TD, CE) independently reviewed the list of papers re-
trieved from the electronic searches according to the pre-deﬁned inclu-
sion criteria. Any disagreement was resolved with discussion after an
independent review of the list of papers by a third author (MC). The
study selection process is reported in the supplementary material (Ap-
pendix A).
2.7. Data extraction and management
Two authors (TD, CE) independently extracted the data from the list
of included papers. For papers that only reported partial data (e.g. not
reporting both pre and post treatment values for negative symptoms)
original authors were contacted via email and asked to provide the un-
published scores necessary for the analysis. Authorswere given 8weeks
to reply to the request and reminded once. Partial data from authors
who did not provide the missing information were not considered in
the analysis. Studies excluded due to missing data were explored with
regards to theirmain characteristics (sample size, type of treatment, du-
ration of treatment, main ﬁndings) to exclude possible biases.
2.8. Risk of bias assessment
Three authors (CE, TD, MC) independently assessed the quality of all
papers using the Clinical Trials Assessment Measure (CTAM) (Wykes,
Steel, Everitt, & Tarrier, 2008) if therewas disagreement a fourth author
provided guidance (TW) and a consensus reached. This tool evaluates
study methodological rigour (e.g. randomisation, blinding, analyses).
All agreed ratings were sent to the study authors for approval. In cases
where authors disagreed, supplementary evidence was requested.
Only ﬁve study authors failed to reply. Comments received from the au-
thors were used to modify the rating.
2.9. Measures of treatment effect
We considered both acute (i.e. end of treatment) and maintenance
(i.e. at follow-up) effectiveness. For continuous measures, effect sizes
were calculated as bias-corrected standardized mean change values
(i.e. Hedges's g and 95% conﬁdence interval) and computed so that a
negative value indicates a favourable outcome (i.e., symptom reduc-
tion) (Hedges & Olkin, 1985). For categorical variables (e.g. dropout
rates) odds ratio (OR) with 95% conﬁdence intervals (CI) were
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calculated. Individual trials were ﬁrst investigated by pairwise, head-to-
headmeta-analyses, and then tested in the networkmeta-analysis. Net-
work meta-analysis can be considered a generalization of pairwise
meta-analysis that compares all pairs. This approach was used to evalu-
ate the effectiveness of CR comparedwith TAU and TAUplus active con-
trol. By comparing three conditions networkmeta-analysis can consider
both the direct and indirect effect of an intervention (See Appendices C,
D and G for additional details).
2.10. Unit of analysis issues
Effectivenesswas estimated by comparing baseline datawith data at
the end of treatment. Treatment retention was estimated by comparing
baseline with follow-up data. Treatment duration, age and gender were
assessed as acute effectiveness moderators with meta-regression. Fol-
low-up duration was assessed as a moderator of treatment retention.
2.11. Missing data
For studies with missing data, we contacted the study team. If the
missing information was not provided, the study was excluded from
the analysis.
2.12. Assessment of heterogeneity
Heterogeneity was assessed with Cochran's Q and I2 statistics
(Huedo-Medina, Sanchez-Meca, Marin-Martinez, & Botella, 2006). Sig-
niﬁcant Q statistics (i.e. p b 0.05) was interpreted as suggestive of het-
erogeneity. For I2, values between 30 and 60% represent moderate
heterogeneity; 75–100% represent considerable heterogeneity. Addi-
tional assessment of heterogeneity was conducted using Baujat plots
(Baujat, Mahe, Pignon, & Hill, 2002). To control for models adequacy
and outliers identiﬁcation we used radial and standardized residuals
plots (Viechtbauer, 2010) (See Appendix G).
2.13. Assessment of reporting biases
Publication bias was evaluated using the Egger's regression test and
a funnel plot of the effect sizes against the standard error (SE). Publica-
tion bias was adjusted using the trim-and-ﬁll procedure (Duval &
Tweedie, 2000). In case of statistically signiﬁcant results, fail-safe n
was calculated. This is the minimum number of additional null studies
necessary to make the result no longer statistically signiﬁcant
(Rosenthal, 1991). An effect size can be regarded as robust if the fail-
safe number exceeds 5 K+10,where K is the number of studies includ-
ed in the meta-analysis (Rosenthal, 1991). We also used the Rosenberg
(2005) method, which calculates the number of studies averaging null
results that would have to be added to the given set of observed out-
comes to reduce signiﬁcance level of the (weighted) average effect
size (based on a ﬁxed-effects model) to a target alpha level (e.g., 0.05).
2.14. Data synthesis
The bias-corrected standardized mean change score (Hedges' g),
standard error and variance were calculated with the Comprehensive
Meta-Analysis version 2.2 (http://www.meta-analysis.com/). Subse-
quent pairwise meta-analyses based on Hedges' g, and network meta-
analysis were carried using R version 3.0.2 (R Core Team, 2013;
Viechtbauer, 2010).
The results of both ﬁxed- and random-effects models were reported
for the pairwise meta-analyses. Fixed-effects models are aimed at mak-
ing a conditional inference only about the studies included in the meta-
analysis and can provide valid inferences under heterogeneity
(Viechtbauer, 2010). The random-effects model provides an inference
about the average effect in the entire population of studies from
which the included studies are assumed to be a random selection. Be-
tween studies variance and variance of the effect size parameters across
the population were estimated with the tau-squared statistics using
Empirical Bayes estimator.We calculated the 95% CI for the heterogene-
ity using theQ-Proﬁlemethod, to assess the extent and relevance of het-
erogeneity (Viechtbauer, 2010). The signiﬁcance level thresholdwas set
at p b 0.05.
2.15. Sensitivity analysis
Sensitivity analysis was performed to evaluate the robustness of the
meta-analysis results. The RCTs considered at high risk of bias (i.e. CTAM
score b 65) were compared with to those considered at low risk (i.e.
CTAM score N 65) (as in Wykes et al., 2011).
Table 1
Results of pairwise meta-analyses: effects of cognitive remediation on negative symptoms versus comparison condition.
Original model Trim and ﬁll analysis
Outcome K
studies
N
participants
Model Hedges'
g
95%CI z p Q I2 p AIC BIC Estimated
missing
study
New
estimate
95%CI p
lower upper lower upper
Negative symptoms
At
post-treatment
45 2511 FE −0.34 −0.42 −0.27 −8.59 b0.01 59.88 0.06 31.76 33.57 0
45 2511 RE −0.35 −0.44 −0.25 −7.23 b0.01 59.88 28% 0.06 32.12 35.74 0
42 2318 RE
(−out)
−0.30 −0.36 −0.22 −7.88 b0.01 32.28 0% 0.83 8.37 11.85 0
At follow-up 15 808 FE −0.47 −0.61 −0.33 −6.54 b0.01 49.60 0.01 42.29 43.00 0
15 808 RE −0.52 −0.80 −0.23 −3.57 b0.01 49.60 74% 0.01 28.44 29.86 0
14 737 RE
(−out)
−0.36 −0.51 −0.21 −5.18 b0.01 11.65 0% 0.56 6.89 8.17 0
Dropout Relative
risk
At post−
treatment
42 2435 FE 0.89 0.75 1.06 −1.29 0.20 37.55 0.62 100.9 102.7 2 0.88 0.74 1.04 0.14
42 2435 RE 0.89 0.75 1.06 −1.29 0.19 37.55 0% 0.62 102.9 106.4 2 0.88 0.74 1.04 0.14
40 2317 RE
(−out)
0.90 0.78 1.05 −1.36 0.18 25.43 0% 0.95 90.18 93.56 1 0.90 0.75 1.07 0.23
FE: ﬁxed-effects model.
RE: random-effects model with Bayes estimator.
RE (−out): random-effects model with Bayes estimator after exclusion of outliers.
*p b 0.01.
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3. Results
3.1. Search results
The literature search produced 487 papers from 387 independent
studies. Two-hundred and twelve of these were excluded as not ﬁtting
the entry criteria. From the remaining pool of 175 reports, after full
paper screening, we were able to include data from 45 independent
studies (see Appendix A). The studies included 2511 participants with
a mean age of 35.1 (SD 6.7) and mostly men (i.e. 71%). Most studies
were carried out in the United States (N= 14), although 15 countries
were represented. The control group was treatment as usual (TAU) in
18 studies and TAU with addition of active control or adjunctive treat-
ment (e.g., computer games or cognitive behavioural therapy) for 26
studies. Negative symptoms were measured with the PANSS in 34
studies, BPRS in 6 and SANS in 5. All studies included data on partici-
pants at baseline and after treatment; 15 included data on participants
at follow-up.
3.2. Bias rating
Overall, the studies included had a medium to high risk of bias (see
Appendix B). Scores on the CTAM ranged between 27 and 87, with
47% of studies scoring below 65.
3.3. Treatment efﬁcacy
One thousand three-hundred and three participants were random-
ized to Cognitive Remediation and 1208 to the control group. Table 1
summarizes the results of the pairwise comparisons. Cognitive Remedi-
ation was effective in reducing levels of negative symptoms at post-
treatment (Fig. 1). Mean effect size (Hedges' g) on negative symptoms
was−0.39 (95%CI:−0.47 to−0.30) in the ﬁxed-effects model with
no signiﬁcant differences with the random-effects (i.e. for AIC and BIC
largely below 10). The fail-safe number was estimated at 1178 using
Rosenthal (1991), and at 819 using Rosenberg (2005). These values
are both higher than the robustness threshold (5 × 45 + 10 = 235).
Fig. 1. Forest plot of the effectiveness of cognitive remediation in the treatment of negative symptoms in schizophrenia (k= 45). Reported the results of the ﬁxed- and the random-effects
models with empirical Bayes estimator with and without outliers.
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In the random-effects model, heterogeneity was low (I2 lower than
30%), the funnel plot was reasonably symmetric (Fig. 2), and no trim-
ming was suggested. Radial plot, the standardized residuals plot, and
the Baujat plot for the random-effects model converged in indicating
three outliers (Eack, Mesholam-Gately, Greenwald, Hogarty, &
Keshavan, 2013; Gharaeipour & Scott, 2012; Vauth et al., 2005) (see
Appendix C Figs. C1, C2, C3). A random-effects model was recalculated
without the outliers, with small change in the effect size (−0.30
[−0.36 to −0.22]) and reduction in heterogeneity (I2 = 0%; 95%CI:
0% to 22%).
Studies with higher methodological quality showed a larger effect
size compared to those with low: CTAM score b 65 (N= 21) ﬁxed-ef-
fects model effect size = −0.27 (95% CI: −0.39 to −0.15); CTAM
score ≥ 65, n = 24, ﬁxed-effects model effect size =−0.40 (95% CI:
−0.51 to−0.30).
3.4. Effects at follow-up
Effectiveness of CRonnegative symptomswasmaintained at follow-
up, with no decrement of the effect size in all models (Table 1). The
model without outliers had zero heterogeneity (I2 = 0%; 95%CI: 0% to
63%).
3.5. Network meta-analysis
Compared to TAU, CR was superior to TAU + other treatments in
both the ﬁxed-effects and random-effects models (Fig. 3). The network
was close (see Appendix D). Q-statistics showed that this result is con-
sistent across studies: whole network (Q=67.36; df= 44; p=0.013);
within designs (Q=56.36; df= 41; p=0.055); between designs (Q=
11.0; df = 3; p= 0.01).
3.6. Treatment moderators
Treatment duration had a very small impact on the estimated effect
size, with studies with longer duration providing a slightly larger effect
size: β=−0.01 (95%CI:−0.013 to−0.003); t=−2.23; p=0.03 (see
Appendix E). In the model with duration of treatment as a moderator,
heterogeneity was low (Test for Residual Heterogeneity: Q = 49.91;
df = 39; p = 0.11; I2 = 23%; 95%CI: 0% to 55%). Age (coefﬁcient =
0.01; −0.01 to 0.02), gender ratio (coefﬁcient = −0.03; −0.08 to
0.02), sample size (coefﬁcient = 0.0; −0.01 to 0.01) had no impact
on the effect size.
Studies using the PANSS had lower but more precise effect size
(−0.35; −0.46 to −0.24; t = −6.46, p b 0.001) than studies using
the BPRS (−0.40; −0.70 to −0.11; t = −2.77, p = 0.008) or the
SANS (−0.38;−0.66 to−0.09; t=−2.68, p= 0.01).
None of the moderators considered had an impact on the effect size
at follow-up.
3.7. Treatment acceptability
Data on dropout were available in 42 studies, including 2435 pa-
tients (1264 randomized to CR and 1171 randomized to the control con-
dition). There were no differences in drop-out rates between
individuals randomized to CR and the control conditions (Fig. 4). In
the random-effects model the funnel plot was reasonably symmetric
(see Appendix F) and the Egger test was negative. However, the trim-
and-ﬁll procedure suggested that 2 studies might be added, still with
no difference between groups (Table 1). In the random-effects model
the heterogeneity was low: I2 = 0% (95%CI: 0% to 37%); Q = 37.55;
df = 41; p= 0.62. Radial plot, the standardized residuals plot, and the
Baujat plot for the random-effects model converged in indicating two
outliers (see Appendix F).
The analysis repeated without the outliers did not alter these esti-
mates: RR = 0.90 (95%CI: 0.78 to 1.05) and I2 = 0% (0% to 8%).
4. Discussion
The currentmeta-analysis is theﬁrst systematic study of the effect of
CR on negative symptoms in people with schizophrenia. The results
demonstrate a small to moderate effect of CR on negative symptoms
at post-therapy with this effect being maintained at follow-up. The re-
sult of the network meta-analysis comparison corroborated the effec-
tiveness of CR not only in comparison to TAU but also in relation to
the active control condition. Overall, the best model had a 95% CI rang-
ing between−0.36 and−0.22, corresponding to a number needed to
treat between 5 and 8.
Methodological quality is important when considering the reliability
of meta-analytic ﬁndings. We found that it did inﬂuence negative
Fig. 3. Shows effect size, using Fixed (Panel A) and Random (Panel B) effectmodels, for CR
on negative symptoms compared to Oth (other active therapy) and TAU (treatment as
usual).
Fig. 2. Funnel plot of the effect sizes against the standard error for the random-effect
model with empirical Bayes estimator (using data from 45 studies). The results of the
Egger test for funnel plot asymmetry are reported at the top.
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symptom reduction but unusually studieswith bettermethodology had
a higher effect size and a narrower 95% CI. This provides further conﬁ-
dence in the reliability of our results as effect sizes tend to increase
with poorer methods due to higher risk of bias. On the contrary our re-
sults suggest that we have minimised the risk of methodological bias.
Amongst studies with high methodological rigour (i.e. CTAM score
over 65)ﬁve had an effect size above 0.7 andmaywarrant closer inspec-
tion to highlight possible mechanisms responsible for negative symp-
tom reduction. These are Twamley, Vella, Burton, Heaton and Jeste
(2012), Vita, De Peri, Barlati, Cacciani, Cisima et al. (2011), Vita, De
Peri, Barlati, Cacciani, Deste et al. (2011), Bowie, McGurk, Mausbach,
Patterson and Harvey (2012), Eack et al. (2013). These programmes de-
livered between 24 and over 100 h of therapy over a period of time
spanning between 12 weeks and 2 years. One common characteristic
amongst these programmes is supporting practice on cognitive tasks
with rehabilitation activities (e.g. supported employment) or
opportunities to reﬂect on how to apply CRT skills in everyday life.
These programs also required frequent personal contact with a facilita-
tor or therapist. It is likely that by providing these elements these pro-
grams facilitated learning consolidation making new cognitive skills
accessible in everyday life. These in turn might have reduced the inﬂu-
ence of behavioural negative symptoms such as poor motivation or
lack of social behaviour. Programs using supported practice and other
methods to maximise transfer of therapy learned skill to everyday life
and those who used a therapist or a facilitator may be more likely to
have an impact on negative symptoms.
Most studies considered were underpowered to detect the re-
ported effect size. To detect an effect size of d= 0.30 with two-tailed
p b 0.05 and 80% power, a study would require a sample of over 120
participants per group. This may explain why most studies did not
report statistically signiﬁcant differences. Future studies aiming to
assess the effectiveness of CR on negative symptoms should consider
Fig. 4. Forest plot of studies’ dropout pairwise analysis.
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the power of their study to detect the beneﬁts given the results of
this meta-analysis.
We did not ﬁnd that CR length inﬂuenced negative symptom reduc-
tion. With only 18% of the studies having a treatment length over
12 weeks this result may be inﬂuenced by a skewed distribution and
limited variability. Intervention frequency is also important in deter-
mining the optimal “dose” of CR and this is also a parameter that differs
across the interventions considered. There is currently limited agree-
ment on how to optimise CR protocols to maximise outcomes and fu-
ture studies should focus on characterising the resource-beneﬁt trade-
off so that this information can be used to develop interventions that
are ﬁt for purpose.
Given the lack of consideration of negative symptom change in the
context of CR there is limited information available in the literature on
potential moderators. One study showed that younger people may
achieve larger beneﬁt on cognitive measures after CR compared to
older participants (Wykes et al., 2009).We explored the potential mod-
erating role of age on negative symptom reduction butwe did not ﬁnd it
to have an effect. Similarly there is limited information in relation to
mediators and active ingredients of CR that may contribute to negative
symptom reduction. A recent study suggested that improvement in ex-
ecutive functioning after CR may be associated with negative symptom
reduction (Farreny et al., 2013). CR may exert a positive effect on nega-
tive symptomalso via its non-speciﬁc components including the contact
with a therapist and the behavioural activation consequent to session
attendance (Vinogradov, Fisher, & Nagarajan, 2013); however these
suggestions require more empirical grounding.
Negative symptomsare not traditionally considered a primary target
for CR. The current study demonstrated that it may have similar effect
sizes to other available pharmacological and behavioural interventions
designed to tackle negative symptoms directly (Fusar-Poli et al.,
2014). The drop-out rate also suggests that CR is acceptable and tolerat-
ed by service users and further recommends this approach as viable and
safe. This is an area that would require further research. Nonetheless,
these results are promising and point to CR as a useful intervention for
reducing the negative symptoms of schizophrenia.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cpr.2016.11.009.
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